HMGN2 (High Mobility Group Nucleosome-Binding Domain 2) is a member of the high-mobility group (HMG) protein family, characterized by its ability to bind chromatin and regulate DNA accessibility. As a non-histone chromatin-associated protein, HMGN2 modulates nucleosome structure and interacts with transcription factors to influence gene expression, DNA repair, and epigenetic regulation. It is ubiquitously expressed in mammalian tissues and plays a role in cellular processes such as differentiation, proliferation, and stress responses.
Antibodies targeting HMGN2 are essential tools for studying its function and localization. These antibodies are typically developed using immunogenic peptides or recombinant HMGN2 protein, enabling specific detection in techniques like Western blotting, immunofluorescence, and chromatin immunoprecipitation (ChIP). Researchers utilize HMGN2 antibodies to investigate its involvement in diseases, including cancer (where it may act as an oncogene or tumor suppressor depending on context), inflammatory disorders, and neurodegenerative conditions.
Studies have also explored HMGN2's role in maintaining stem cell pluripotency and its dynamic behavior during the cell cycle. Validation of HMGN2 antibodies includes verifying cross-reactivity across species and confirming absence of cross-reactivity with other HMGN family members (e.g., HMGN1. HMGN3). Reliable HMGN2 antibodies are critical for elucidating its chromatin-remodeling mechanisms and therapeutic potential in disease models.